WO2004058141A2 - An agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component - Google Patents
An agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component Download PDFInfo
- Publication number
- WO2004058141A2 WO2004058141A2 PCT/KR2003/002859 KR0302859W WO2004058141A2 WO 2004058141 A2 WO2004058141 A2 WO 2004058141A2 KR 0302859 W KR0302859 W KR 0302859W WO 2004058141 A2 WO2004058141 A2 WO 2004058141A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ginsenoside
- expression
- bcl
- cells
- treated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an agent for controlling Bcl-2 expression comprising ginsenoside FI (20-O- ⁇ -D-glucopyranosyl-20(S)- protopanaxatriol) represented by the following formula 1 as an active component.
- Ultraviolet radiation is a part of solar rays with 200-400nm of wavelength and is a part of the electromagnetic spectrum; especially UVB (Ultraviolet-B) with 280-320nm of wavelength is the major part of the ultraviolet radiation to cause skin aging leading to skin-burn and skin cancer.
- UVB Ultraviolet-B
- DNA, proteins, lipids, etc., in cells are damaged and thereby generate sunburn-cells.
- These sunburn-cells undergo apoptosis, accompanied by DNA fragmentation, activation of caspase, and the like.
- High-dose radiation on the cell causes serious DNA damages that are not recovered from; and the apoptosis prevents the cell from developing to a tumor by inducing the cell to die. Therefore, in order to prevent cancer and maintain cell homeostasis, it is very important to induce or to prevent apoptosis of the cell selectively according to the degree of cell damages.
- Bcl-2 plays a very important role in the process of apoptosis of the skin cell.
- the Bcl-2 gene encodes 26kDa protein present in a nuclear membrane and an outer membrane of mitochondria.
- Bcl-2 is a protein that inhibits apoptosis of a cell by adhering to a protein such as Bax, which accelerates the apoptosis, to inhibit its function. Therefore, apoptosis of a cell can be determined by the concentration ratio of Bcl-2 and Bax.
- UVB irradiation has been known to decrease Bcl-2 expression of human keratinocyte. Furthermore, Bcl-2-transfected HaCaT cells or Bcl-2- overexpressing transgenic mice were shown to be resistant to UVB-induced apoptosis. However, over-expression of Bcl-2 prevents apoptosis of a cell with serious DNA damage and thereby causes a cancer. Therefore, it is very important to control the expression of Bcl-2 selectively.
- ginsenoside FI which obtained from purified ginseng saponin, protects human HaCaT cells from UVB-induced apoptosis by maintaining constant levels of Bcl-2. That is, the present inventors found that ginsenoside FI controls the expression of Bcl-2 and thereby inhibits the apoptosis of cells, and so accomplished the present invention.
- an object of the present invention is to provide an agent for controlling Bcl-2 expression comprising ginsenoside FI as an active component.
- Another objection of the present invention is to provide a promoter or an inhibitor of apoptosis comprising ginsenoside FI as an active component.
- the present invention provides an agent for controlling Bcl-2 expression comprising ginsenoside FI represented by the following formula 1 as an active component.
- Ginsenoside FI protects these cells against low-dose radiation of UVB- induced apoptosis by maintaining constant levels of Brn-3a and the corresponding inhibition of Bcl-2 downregulation. That is, ginsenoside FI itself does not promote the Bcl-2 expression, but inhibits the downregulation of Bcl-2 caused by ultraviolet radiation. On the contrary, under the high-dose radiation of ultraviolet rays, it induces the decrease of Bcl-2 expression to promote apoptosis.
- ginsenoside FI inhibits the decrease of Bcl-2 expression under low-dose radiation of ultraviolet rays resultingly to prevent apoptosis of cells; however induces apoptosis under the high-dose radiation of ultraviolet rays, on the contrary; and thereby prevents skin cancer. Therefore, ginsenoside FI may be used as an anti-aging material inhibiting cell damages.
- the present invention confirmed that ginsenoside FI controls the expression of Brn-3a, a transcription factor of Bcl-2, and thereby can maintain the degree of Bcl-2 expression to a normal level.
- ginsenoside FI can prevent apoptosis by maintaining the degree of Bcl-2 expression in a cell to desirable level.
- ginsenoside FI itself does not promote the Bcl-2 expression.
- Fig. 1 is a graph showing viabilities of HaCaT skin cells obtained from the result of MTT assay, wherein cells treated with ginsenoside FI and exposed to ultraviolet radiation were compared with a control (cells) untreated with ginsenoside FI .
- Fig. 2 shows the changes of shapes of the cells, wherein cells treated with ginsenoside FI and exposed to ultraviolet radiation were compared with a control untreated with ginsenoside FI .
- Fig. 3 shows the degrees of DNA fragmentation of cells, wherein cells treated with ginsenoside FI and exposed to ultraviolet radiation were compared with a control untreated with ginsenoside FI .
- Fig. 4 shows the degrees of PARP segmentation in cells obtained from the result of Western blotting, wherein cells treated with ginsenoside FI and exposed to ultraviolet radiation were compared with a control untreated with ginsenoside FI .
- Fig. 5 shows the degrees of Bcl-2 expression with mRNA level, wherein cells treated with ginsenoside FI and exposed to ultraviolet radiation were compared with a control untreated with ginsenoside F 1.
- Fig. 6 shows the degrees of the expression of Brn-3a, a transcription factor of Bcl-2, obtained from Western blotting, wherein cells treated with ginsenoside FI and exposed to ultraviolet radiation were compared with a control untreated with ginsenoside F 1.
- Hsp 70 means that a same amount of protein was used.
- the extract (1-butanol extract) was dissolved in a small amount of methanol, and a large amount of ethylacetate was added thereto to obtain precipitation.
- the precipitation was dried to obtain 70g of purified ginseng saponin extract.
- Example 1 Inhibition of apoptosis of HaCaT cells induced by ultraviolet radiation, when treated with ginsenoside FI
- Human keratinocyte, HaCaT obtained from Dr. Fusenig in German Cancer Research Center (DKFZ) was cultured in Dulbecco's modified Eagle's Medium (DMEM; Gibco 1210-0038) containing 10% of fetal bovin serum at 37 ° C and 5% of C0 2 .
- DMEM Dulbecco's modified Eagle's Medium
- step 1 Cells cultured in step 1 were treated with trypsin to obtain single cell suspension, and seeded into 6- well flask with 2xl0 5 /well, then cultured for 24 hours. After that, the cells were cultured again in a new DMEM not containing fetal bovin serum for 24 hours, then treated with 1, 5, 10 ⁇ M of ginsenoside FI . Ginsenoside FI was dissolved in 100% ethanol and added to be 1/1000 of the medium concentration. After 24 hours of treatment with ginsenoside FI, the cell cultures were washed with phosphate buffered saline (PBS), and exposed to 60-120 mJ/c ⁇ of UVB radiation with a state containing PBS.
- PBS phosphate buffered saline
- the PBS was removed and medium was changed with a fresh one containing the same concentration of ginsenoside FI.
- the cells untreated with ginsenoside FI were cultured as a control.
- 3-[4,5-dimethyl tetrazole]-2,5-diphenyltetrazolium bromide (MTT, Sigma) was added to all the cells treated and untreated with ginsenoside FI, then cultured 4 hours at 37 ° C .
- the cells were dissolved with dimethylsulfoxide, then optical density (OD) of formazan dye generated at 540nm was measured with ELISA reader (Thermo Max, Molecular Devices Co.).
- OD value of the cells not-exposed to the UVB was given 100%, then the relative values of the other cells were calculated and determined as viabilities thereof.
- the results are shown in Fig. 1.
- the cells treated with ginsenoside FI showed 1.5 times more inhibition of apoptosis compared with those untreated, when exposed to the UVB. However, under the 120 mJ/c ⁇ of UVB radiation, the cells treated with ginsenoside FI showed more apoptosis than those untreated.
- step 1 Cells cultured in step 1 were treated with trypsin to obtain single cell suspension, and seeded into 6-well flask with 2xl0 5 /well, then cultured for 24 hours. After that the cells were cultured again in a new DMEM not containing fetal bovin serum for 24 hours, then treated with 5 ⁇ M of ginsenoside FI . After 24 hours of treatment with ginsenoside FI, the cultures were washed with phosphate buffered saline (PBS), and exposed to 60mJ/c ⁇ of UVB radiation with a state containing PBS. Then, the PBS was removed and medium was changed with a fresh one containing the same concentration of ginsenoside FI . In addition, the cells untreated with ginsenoside FI were cultured as a control.
- PBS phosphate buffered saline
- Reaction termination buffer TUNEL Apoptosis detection kit, Upstate, USA
- blocking solution TUNEL Apoptosis detection kit, Upstate, USA
- Avidin-FITC TUNEL Apoptosis detection kit, Upstate, USA
- Step 1 Cell line and cell culture Same procedures of step 1 of Example 1 were performed.
- Cells cultured in step 1 were treated with trypsin to obtain single cell suspension, and seeded into 6- well flask with 2xl0 5 /well, then cultured for 24 hours. After that the cells were cultured again in a new DMEM not containing fetal bovin serum for 24 hours, then treated with 5 ⁇ M of ginsenoside FI . After 24 hours of treatment with ginsenoside FI, the cell cultures were washed with phosphate buffered saline (PBS), and exposed to ⁇ OmJ/c ⁇ of UVB radiation with a state containing PBS. Then, the PBS was removed and medium was changed with a fresh one containing 5 ⁇ M of ginsenoside FI. In addition, the cells untreated with ginsenoside FI were cultured as a control.
- PBS phosphate buffered saline
- the blots reacted were exposed to X-ray Fuji film and developed to observe the degree of protein expression. Bands on the film were scanned with PowerLook 2100 XL (umax) and analyzed with an image-analyzing program of ImageMaster 2D Elite (Amersham Bioscience). The amount of PARP protein segmentation was estimated with a relative value compared with that of control. The cells treated with ginsenoside FI showed 1.4 times decrease of PARP protein segmentation compared with those untreated, when exposed to the UVB. The results are shown in Fig. 4.
- Step 1 Cell line and cell culture Same procedures of step 1 of Example 1 were performed.
- step 1 Cells cultured in step 1 were treated with trypsin to obtain single cell suspension, and seeded into 6- well flask with 2xl0 5 /well then cultured for 24 hours. After that the cells were cultured again in a new DMEM not containing fetal bovin serum for 24 hours, then treated with 5 ⁇ M of ginsenoside FI .
- the cell cultures were washed with phosphate buffered saline (PBS), and exposed to ⁇ OmJ/cn of UVB radiation with a state containing PBS. Then, the PBS was removed and medium was changed with a fresh one containing 5 ⁇ M of ginsenoside FI . In addition, the cells untreated with ginsenoside FI were cultured as a control.
- PBS phosphate buffered saline
- PBS phosphate buffered saline
- the PBS was removed and medium was changed with a fresh one containing 5 ⁇ M of ginsenoside FI.
- the cells that are not treated with ginsenoside FI were cultured as a control.
- all the cell cultures treated and untreated with ginsenoside FI were washed with phosphate buffered saline (PBS), and cells were collected by treating with trypsin, and which were treated with 8M of urea, 2% of CHAPS, 50mM of DTT, 2M of thiourea, 2mM of PMSF and 500 ⁇ i of protein extract buffer solution of 100 g/mi- leupeptine, then left at room temperature for 10 minutes; and then centrifuged with 15,000g of gravity for 10 minutes at 4 ° C , and supernatant was collected then protein was quantitated with BIO-Rad Protein Dye ReagentTM.
- ginsenoside FI of the present invention inhibits the decrease of Bcl-2 expression caused by ultraviolet radiation to inhibit apoptosis induced from ultraviolet radiation, on the contrary under the high-dose ultraviolet radiation, ginsenoside FI promotes apoptosis of cell to prevent the cell from developing as a cancer cell.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004563021A JP4654040B2 (en) | 2002-12-28 | 2003-12-27 | Expression regulator of transcriptional regulator Brn-3a containing ginsenoside F1 as an active ingredient |
AU2003289538A AU2003289538A1 (en) | 2002-12-28 | 2003-12-27 | An agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component |
US10/539,012 US20070155829A1 (en) | 2002-12-28 | 2003-12-27 | Agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component |
EP03779032A EP1575599A2 (en) | 2002-12-28 | 2003-12-27 | An agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component |
US12/135,663 US8258272B2 (en) | 2002-12-28 | 2008-06-09 | Agent for controlling Bcl-2 expression comprising ginsenoside F1 as an active component |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0085716 | 2002-12-28 | ||
KR1020020085716A KR100820072B1 (en) | 2002-12-28 | 2002-12-28 | Control agent of Bcl-2 expression being Ginsenoside F1 as active component |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/539,012 A-371-Of-International US20070155829A1 (en) | 2002-12-28 | 2003-12-27 | Agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component |
US12/135,663 Continuation US8258272B2 (en) | 2002-12-28 | 2008-06-09 | Agent for controlling Bcl-2 expression comprising ginsenoside F1 as an active component |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004058141A2 true WO2004058141A2 (en) | 2004-07-15 |
WO2004058141A3 WO2004058141A3 (en) | 2004-12-02 |
Family
ID=36241075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2003/002859 WO2004058141A2 (en) | 2002-12-28 | 2003-12-27 | An agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component |
Country Status (7)
Country | Link |
---|---|
US (2) | US20070155829A1 (en) |
EP (1) | EP1575599A2 (en) |
JP (1) | JP4654040B2 (en) |
KR (1) | KR100820072B1 (en) |
CN (1) | CN100404034C (en) |
AU (1) | AU2003289538A1 (en) |
WO (1) | WO2004058141A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007107965A1 (en) | 2006-03-23 | 2007-09-27 | Actelion Pharmaceuticals Ltd | Cyclohexyl or piperidinyl carboxamide antibiotic derivatives |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101820854A (en) | 2007-10-31 | 2010-09-01 | 株式会社太平洋 | Use of melanin biosynthesis inhibitors from korean ginseng and the cosmetic composition containing thereof for skin whitening |
WO2012031103A2 (en) * | 2010-09-01 | 2012-03-08 | Case Western Reserve University | Inhibitors of bcl-2 |
KR101777920B1 (en) * | 2015-07-27 | 2017-09-14 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | The composition containing ginsenoside F1 for removing amyloid plaques |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030037005A (en) * | 2001-11-01 | 2003-05-12 | 주식회사 태평양 | Manufacturing method of Compound K and Ginsenoside F1 from ginseng ginsenosides |
KR20030060017A (en) * | 2002-01-05 | 2003-07-12 | 주식회사 태평양 | Microemulsion having Ginsenoside F1 by nano-emulsion technology, and skin care and pharmaceutical compositions for external applications utilizing thereof |
KR20030094523A (en) * | 2002-05-27 | 2003-12-18 | 주식회사 태평양 | Microemulsion comprising metabolites of ginseng saponin as effective component and preparation method, and skin care compositions for antiaging agent utilizing thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2695561B1 (en) | 1992-09-17 | 1994-12-02 | Lvmh Rech Gie | Cosmetic or dermatological composition containing at least one ginsenoside-type saponin, and its applications, in particular for hair care. |
US6001992A (en) * | 1999-01-07 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of novel anti-apoptotic bcl-2-related proteins |
JP3193542B2 (en) * | 1993-09-08 | 2001-07-30 | カネボウ株式会社 | Anti-aging skin cosmetics |
KR100192678B1 (en) * | 1995-06-07 | 1999-06-15 | 손경식 | Processed ginseng product having an increased pharmacological activity |
JP2001511344A (en) * | 1997-07-25 | 2001-08-14 | ニューロヴェックス リミテッド | Use of transcription factor Brn-3a |
KR100361433B1 (en) * | 1998-05-28 | 2003-01-24 | 주식회사 태평양 | Anti-aging cosmetic compositions containing an Extract obtained from Panax ginseng |
US6261603B1 (en) * | 1999-05-11 | 2001-07-17 | Mcelwain Elizena A. | Skin cream |
JP4549625B2 (en) * | 2002-01-05 | 2010-09-22 | 株式會社アモーレパシフィック | Finely emulsified particles containing ginseng saponin metabolites as active ingredients, a method for producing the same, and a cosmetic composition for preventing skin aging containing the same |
KR200337005Y1 (en) | 2003-07-09 | 2003-12-31 | (주) 그린죤 | Autometic spray machine of perfume liquid |
KR200360017Y1 (en) | 2004-06-01 | 2004-08-26 | 김길평 | Wind velocity reduction equipment for bridge |
KR200394523Y1 (en) | 2005-06-20 | 2005-09-02 | 이기태 | Mutipupose case set |
-
2002
- 2002-12-28 KR KR1020020085716A patent/KR100820072B1/en active IP Right Grant
-
2003
- 2003-12-27 EP EP03779032A patent/EP1575599A2/en not_active Withdrawn
- 2003-12-27 AU AU2003289538A patent/AU2003289538A1/en not_active Abandoned
- 2003-12-27 JP JP2004563021A patent/JP4654040B2/en not_active Expired - Fee Related
- 2003-12-27 WO PCT/KR2003/002859 patent/WO2004058141A2/en active Application Filing
- 2003-12-27 US US10/539,012 patent/US20070155829A1/en not_active Abandoned
- 2003-12-27 CN CNB2003801078408A patent/CN100404034C/en not_active Expired - Fee Related
-
2008
- 2008-06-09 US US12/135,663 patent/US8258272B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030037005A (en) * | 2001-11-01 | 2003-05-12 | 주식회사 태평양 | Manufacturing method of Compound K and Ginsenoside F1 from ginseng ginsenosides |
KR20030060017A (en) * | 2002-01-05 | 2003-07-12 | 주식회사 태평양 | Microemulsion having Ginsenoside F1 by nano-emulsion technology, and skin care and pharmaceutical compositions for external applications utilizing thereof |
KR20030094523A (en) * | 2002-05-27 | 2003-12-18 | 주식회사 태평양 | Microemulsion comprising metabolites of ginseng saponin as effective component and preparation method, and skin care compositions for antiaging agent utilizing thereof |
Non-Patent Citations (3)
Title |
---|
KO S.R. ET AL: 'Enzymatic preparation of ginsenosides Rg2, Rh1, and F1' CHEM. PHARM. BULL. vol. 51, no. 4, April 2003, TOKYO, pages 404 - 408, XP002986275 * |
LEE E.H. ET AL.: 'Ginsenoside F1 protects human HaCaT keratinocytes from ultraviolet-B-induced apoptosis by maintaining constant levels of Bcl-2' JOURNAL OF INVEST. DERMATOL. vol. 121, no. 3, September 2003, pages 607 - 613, XP008102382 * |
ZHANG Y.W. ET AL.: 'Effects of ginsenosides from Panax ginseng on cell-to-cell communication function mediated by gap junctions' PLATA MED. vol. 67, no. 5, July 2001, pages 417 - 422, XP008102965 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007107965A1 (en) | 2006-03-23 | 2007-09-27 | Actelion Pharmaceuticals Ltd | Cyclohexyl or piperidinyl carboxamide antibiotic derivatives |
Also Published As
Publication number | Publication date |
---|---|
EP1575599A2 (en) | 2005-09-21 |
WO2004058141A3 (en) | 2004-12-02 |
KR100820072B1 (en) | 2008-04-10 |
AU2003289538A1 (en) | 2004-07-22 |
CN100404034C (en) | 2008-07-23 |
JP4654040B2 (en) | 2011-03-16 |
AU2003289538A8 (en) | 2004-07-22 |
CN1732010A (en) | 2006-02-08 |
JP2006512384A (en) | 2006-04-13 |
US20080261899A1 (en) | 2008-10-23 |
KR20040059139A (en) | 2004-07-05 |
US20070155829A1 (en) | 2007-07-05 |
US8258272B2 (en) | 2012-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jiang et al. | Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3 | |
Lim et al. | Naringenin‐induced apoptotic cell death in prostate cancer cells is mediated via the PI3K/AKT and MAPK signaling pathways | |
Park et al. | Induction of apoptosis and inhibition of telomerase activity in human lung carcinoma cells by the water extract of Cordyceps militaris | |
Nakasu et al. | bcl-2 protein expression in tumors of the central nervous system | |
Thompson et al. | Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression | |
Staibano et al. | Poly (adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region | |
US8258272B2 (en) | Agent for controlling Bcl-2 expression comprising ginsenoside F1 as an active component | |
Sclabas et al. | Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-κB signaling pathway with the anti-epidermal growth factor antibody IMC-C225 | |
Choi et al. | Baicalein inhibits the migration and invasion of B16F10 mouse melanoma cells through inactivation of the PI3K/Akt signaling pathway | |
PT892643E (en) | METHODS FOR INHIBITING AN IMMUNITY RESPONSE BLOCKING THE GP39 / CD40 AND CTLA4 / CD28 / B7 CIRCUITS AND USES FOR THE EFFECT | |
MX9804009A (en) | Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor. | |
Gunasekaran et al. | Anti-inflammatory and anticancer effects of p-methoxycinnamic acid, an active phenylpropanoid, against 1, 2-dimethylhydrazine-induced rat colon carcinogenesis | |
Ai et al. | Arsenic trioxide induces gallbladder carcinoma cell apoptosis via downregulation of Bcl-2 | |
Hall et al. | Maspin reduces prostate cancer metastasis to bone | |
Wright et al. | A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts | |
JP4814870B2 (en) | Skin damage preventing composition containing ginsenoside F1 and EGCG | |
Abe et al. | Inhibition of nucleolar function and morphological change by adriamycin associated with heat shock protein 70 accumulation | |
Suzuki et al. | Chemotherapeutic agent CPT-11 induces the new expression of the apoptosis initiator to the cytoplasm | |
Paraskeva et al. | Are different events involved in the development of sporadic versus hereditary tumours? The possible importance of the microenvironment in hereditary cancer. | |
Scotlandi et al. | Pre‐Treatment of human osteosarcoma cells with N‐methylformamide enhances P‐glycoprotein expression and resistance to doxorubicin | |
KR101894769B1 (en) | Composition Comprising Short Interfering RNAs for Preventing or Treating Neurofibrosarcoma | |
Khazaei et al. | Anticancer Effect of Carob Bean Extract on Human Prostate Cancer Cell Lines: Apoptosis Induction and Bax/Bcl-2 Ratio Improvement | |
KR100408916B1 (en) | An anticancer drug comprising a mycolactone, an antisense Rb oligonucleotide that decreases human retinoblastoma protein expression and an anticancer drug comprising a mycolactone and the said antisense Rb oligonucleotide | |
Chen et al. | Elevated expression of ETS-1 gene in a metastatic, tumorigenic human prostate epithelial cell line transformed by the v-Ki-ras oncogene | |
Tabana | Anti-Tumor Study of Scopoletin and Rubbing-Mercapto-Nitrile from Nicotiana Glauca |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003779032 Country of ref document: EP Ref document number: 2004563021 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A78408 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003779032 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10539012 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10539012 Country of ref document: US |